Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: Results from ATTAIN

Paul W. Jones, David Singh, Alvar Agusti, Eric D. Bateman, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta, Esther Garcia Gil
European Respiratory Journal 2012 40: 195; DOI:
Paul W. Jones
1St George's, University of London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Singh
2Medicines Evaluation Unit Ltd, Manchester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alvar Agusti
3Thorax Institute, Hospital Clínic, Barcelona, and CIBER Enfermedades Respiratorias and Fundació Caubet-Cimera, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric D. Bateman
4University of Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosa Lamarca
5Almirall S.A, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gonzalo de Miquel
5Almirall S.A, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Caracta
6Forest Research Institute, NJ, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther Garcia Gil
5Almirall S.A, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Introduction: COPD exacerbations can lead to considerable morbidity and mortality.

Aims: ATTAIN investigated the effect of twice-daily (BID) aclidinium bromide, a long-acting muscarinic antagonist, on exacerbations in patients with moderate to severe COPD.

Methods: In this 24-week, randomised, double-blind trial, 819 patients (mean±SD FEV1 56.8±12.8% predicted) received aclidinium (200 µg or 400 µg) BID or placebo. Prior exacerbation history was not an inclusion criterion. Exacerbations were assessed by healthcare resource utilisation (HCRU; increased symptoms on ≥2 consecutive days requiring a change in treatment) and the EXAcerbations of Chronic pulmonary disease Tool (EXACT; persistent increase in total score of ≥9 points for ≥3 days or ≥12 points for ≥2 days).

Results: EXACT captured more exacerbations per patient per year than HCRU (EXACT: 1.0, 0.98 and 1.39 for aclidinium 200 µg, 400 µg and placebo, respectively; HCRU: 0.43, 0.40 and 0.60, respectively). Exacerbation rates were significantly lower for both aclidinium doses compared with placebo and rate ratio differences were: EXACT: 200 µg, 0.72 [p=0.017] and 400 µg, 0.71 [p=0.012]; HCRU: 200 µg, 0.72 [p=0.043] and 400 µg, 0.67 [p=0.020]; corresponding to a rate reduction of about 28% with aclidinium using each method.

Conclusions: More than twice as many events were recorded using EXACT compared with HCRU. Aclidinium 200 µg and 400 µg BID reduced exacerbations compared with placebo as assessed by HCRU and EXACT. The proportional improvement observed with treatment was similar irrespective of the method used.

This study was supported by Almirall S.A., Barcelona, Spain, and Forest Laboratories, Inc., New York, USA.

  • COPD - exacerbations
  • COPD - management
  • Bronchodilators
  • © 2012 ERS
Previous
Back to top
Vol 40 Issue Suppl 56 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: Results from ATTAIN
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: Results from ATTAIN
Paul W. Jones, David Singh, Alvar Agusti, Eric D. Bateman, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta, Esther Garcia Gil
European Respiratory Journal Sep 2012, 40 (Suppl 56) 195;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: Results from ATTAIN
Paul W. Jones, David Singh, Alvar Agusti, Eric D. Bateman, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta, Esther Garcia Gil
European Respiratory Journal Sep 2012, 40 (Suppl 56) 195;
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma
  • Maintenance of IRF1 by MAPK inhibition: A mechanism by which DUSP1 reduces glucocorticoid inhibition of CXCL10
  • Increased expression of ADRB2, CHRM3 and glucocorticoid alpha receptor genes in blood leukocytes of COPD patients
Show more 5.1 Airway Pharmacology and Treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society